azathioprine has been researched along with Alveolitis, Fibrosing in 112 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increased risks of death and hospitalization were observed in patients with idiopathic pulmonary fibrosis who were treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo." | 9.16 | Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. ( Anstrom, KJ; King, TE; Lasky, JA; Martinez, FJ; Raghu, G, 2012) |
| "The purpose of the study was to establish the efficacy of treatment with intravenous cyclophosphamide pulses and oral corticoids in idiopathic pulmonary fibrosis, compared with the standard treatment with corticoids and azathioprine." | 9.14 | [Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis]. ( Arroyo-Cózar, M; Herrero, A; Juarros, S; Macías, E; Roig, V; Vielba, D, 2010) |
| " This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease." | 9.12 | A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. ( Black, CM; Denton, CP; Desai, S; du Bois, RM; Ellis, RW; Emery, P; Foley, NM; Goh, NS; Herrick, AL; Hoyles, RK; Lees, B; McHugh, NJ; Newlands, P; Pearson, SB; Roberts, C; Veale, DJ; Wells, AU; Wellsbury, J, 2006) |
| "Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone." | 9.11 | High-dose acetylcysteine in idiopathic pulmonary fibrosis. ( Behr, J; Buhl, R; Capron, F; Corvasce, G; Costabel, U; De Vuyst, P; Dekhuijzen, R; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Montanari, M; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B, 2005) |
| "Twenty-seven newly diagnosed patients with idiopathic pulmonary fibrosis (IPF) who were previously untreated for IPF were enrolled in a prospective, double-blind, randomized, placebo-controlled study to compare the therapeutic effect of combined prednisone/azathioprine (n = 14) with prednisone plus placebo (n = 13)." | 9.07 | Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. ( Cain, K; Depaso, WJ; Dreis, DF; Hammar, SP; Hutchinson, J; Pardee, NE; Raghu, G; Wetzel, CE; Winterbauer, RH, 1991) |
| "The prognosis of idiopathic pulmonary fibrosis is poor, it amounts to 4-6 years (after beginning of the symptoms)." | 6.65 | [Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or d-penicillamine (author's transl)]. ( Amthor, M; Kronenberger, H; Meier-Sydow, J; Riemann, H; Rust, M; Thiel, C, 1979) |
| "Colchicine has been reported to suppress fibroblast growth factors and to inhibit collagen deposition." | 5.29 | Colchicine in the treatment of pulmonary fibrosis. ( Coles, DT; DeRemee, RA; Douglas, WW; McDougall, JC; Peters, SG, 1993) |
| "Increased risks of death and hospitalization were observed in patients with idiopathic pulmonary fibrosis who were treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo." | 5.16 | Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. ( Anstrom, KJ; King, TE; Lasky, JA; Martinez, FJ; Raghu, G, 2012) |
| "The purpose of the study was to establish the efficacy of treatment with intravenous cyclophosphamide pulses and oral corticoids in idiopathic pulmonary fibrosis, compared with the standard treatment with corticoids and azathioprine." | 5.14 | [Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis]. ( Arroyo-Cózar, M; Herrero, A; Juarros, S; Macías, E; Roig, V; Vielba, D, 2010) |
| " This suggests that treatment of pulmonary fibrosis in SSc with low-dose prednisolone and IV CYC followed by AZA stabilizes lung function in a subset of patients with the disease." | 5.12 | A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. ( Black, CM; Denton, CP; Desai, S; du Bois, RM; Ellis, RW; Emery, P; Foley, NM; Goh, NS; Herrick, AL; Hoyles, RK; Lees, B; McHugh, NJ; Newlands, P; Pearson, SB; Roberts, C; Veale, DJ; Wells, AU; Wellsbury, J, 2006) |
| "Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone." | 5.11 | High-dose acetylcysteine in idiopathic pulmonary fibrosis. ( Behr, J; Buhl, R; Capron, F; Corvasce, G; Costabel, U; De Vuyst, P; Dekhuijzen, R; Demedts, M; Flower, CD; Jansen, HM; Lankhorst, I; Laurent, F; MacNee, W; Montanari, M; Nicholson, AG; Petruzzelli, S; Rodriguez-Becerra, E; Sardina, M; Thomeer, M; van den Bosch, JM; Verbeken, EK; Verschakelen, J; Wallaert, B, 2005) |
| "Twenty-seven newly diagnosed patients with idiopathic pulmonary fibrosis (IPF) who were previously untreated for IPF were enrolled in a prospective, double-blind, randomized, placebo-controlled study to compare the therapeutic effect of combined prednisone/azathioprine (n = 14) with prednisone plus placebo (n = 13)." | 5.07 | Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. ( Cain, K; Depaso, WJ; Dreis, DF; Hammar, SP; Hutchinson, J; Pardee, NE; Raghu, G; Wetzel, CE; Winterbauer, RH, 1991) |
| "Based on available data, partly still unpublished, pirfenidone appears to improve progression-free survival and, to a lesser extent, pulmonary function in patients with idiopathic pulmonary fibrosis." | 4.86 | Non-steroid agents for idiopathic pulmonary fibrosis. ( Balduzzi, S; Cerri, S; D'Amico, R; Del Giovane, C; Luppi, F; Richeldi, L; Spagnolo, P; Walters, EH, 2010) |
| "Current guidelines support the use of corticosteroids and azathioprine as one possible treatment strategy for idiopathic pulmonary fibrosis (IPF)." | 3.74 | Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase. ( Adhikari, NK; Cole, DE; Friedman, O; Mintz, S; Perri, D; Piliotis, E, 2007) |
| "Because of the fibrosing alveolitis associated with hepatitis C-related cryoglobulinemia, immunosuppression was started with high-dosage prednisone and azathioprine." | 3.74 | [Fibrosing alveolitis with hepatitis C-related cryoglobulinemia]. ( Dalhoff, K; Heyer, P; Rupp, J; Schaaf, B; Witte, L, 2008) |
| "To compare the effects of treatment of pulmonary fibrosis (PF) by the Chinese herbal medicines, Radix Salviae miltiorrhizae (C1), Radix Astragalus membranaceus (C2) and Caulis Tripterygium wilfordii (C3); western drugs, hydrocortisone (W1) and azathioprine (W2), and combined W2 with C3." | 3.72 | [Experimental study on treatment of pulmonary fibrosis by Chinese drugs and integrative Chinese and Western medicine]. ( Cai, HR; Dai, LJ; Hou, J, 2004) |
| "A 24-year-old female patient with rapidly progressive renal failure secondary to membrano-proliferative glomerulonephritis is thought to have subsequently had acute interstitial pneumonitis as a consequence of azathioprine therapy." | 3.66 | Interstitial pneumonitis associated with azathioprine therapy. ( Weisenburger, DD, 1978) |
| "The prognosis of idiopathic pulmonary fibrosis is poor, it amounts to 4-6 years (after beginning of the symptoms)." | 2.65 | [Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or d-penicillamine (author's transl)]. ( Amthor, M; Kronenberger, H; Meier-Sydow, J; Riemann, H; Rust, M; Thiel, C, 1979) |
| "The treatment of idiopathic pulmonary fibrosis (IPF) remains controversial." | 2.43 | Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. ( Nathan, SD, 2006) |
| "Prednisone has been the mainstay of therapy since its release for clinical use in 1948." | 2.43 | Current perspectives on the treatment of idiopathic pulmonary fibrosis. ( Collard, HR; King, TE; Walter, N, 2006) |
| "Idiopathic Pulmonary Fibrosis (IPF) or Usual Interstitial Pneumonia (UIP) is a form of chronic fibrosing interstitial pneumonia of unknown aetiology, with progressively deteriorating respiratory function and ultimately death from respiratory failure." | 2.42 | Immunomodulatory agents for idiopathic pulmonary fibrosis. ( Davies, HR; Richeldi, L; Walters, EH, 2003) |
| "A RECENTLY MODIFIED CONCEPT: Idiopathic pulmonary fibrosis (IPF) is characterized by dyspnea on exertion, diffuse radiological infiltrates and alterations in respiratory function." | 2.41 | [Treatment of pulmonary fibrosis]. ( Cottin, V, 2002) |
| "The severity of pulmonary fibrosis is not associated with rheumatologic symptoms or the duration of the associated RA, nor is there any clear relation to the extraarticular features of RA or serologic findings." | 2.37 | Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. ( Roschmann, RA; Rothenberg, RJ, 1987) |
| "Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with a characteristic presentation of upper lobe emphysema and lower lobe fibrosis." | 1.39 | Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension--clinical management. ( Cottin, V, 2013) |
| "Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP." | 1.38 | Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura. ( Berkahn, L; Child, N; O'Carroll, M, 2012) |
| "Idiopathic pulmonary fibrosis still has to be diagnosed by elimination." | 1.29 | [Treatment of idiopathic pulmonary fibrosis]. ( Nicod, LP, 1995) |
| "Colchicine has been reported to suppress fibroblast growth factors and to inhibit collagen deposition." | 1.29 | Colchicine in the treatment of pulmonary fibrosis. ( Coles, DT; DeRemee, RA; Douglas, WW; McDougall, JC; Peters, SG, 1993) |
| "Prednisone was the drug of choice for therapy." | 1.28 | Management for interstitial lung disease. State of the art. ( Moser, KM; Smith, CM, 1989) |
| "A minority of patients with cryptogenic fibrosing alveolitis (idiopathic pulmonary fibrosis) respond to treatment with corticosteroids." | 1.26 | Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. ( Haslam, PL; Rudd, RM; Turner-Warwick, M, 1981) |
| "A case of desquamative fibrosing alveolitis beginning in early infancy is described." | 1.25 | Desquamative fibrosing alveolitis unresponsive to steroid or cytotoxic therapy. ( Barnes, SE; Godfrey, S; Millward-Sadler, GH; Roberton, NR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (42.86) | 18.7374 |
| 1990's | 24 (21.43) | 18.2507 |
| 2000's | 28 (25.00) | 29.6817 |
| 2010's | 12 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cottin, V | 3 |
| Valenzuela, C | 1 |
| Ancochea, J | 1 |
| Zold, E | 1 |
| Bodolay, E | 1 |
| Dezső, B | 1 |
| Soos, G | 1 |
| Nakken, B | 1 |
| Szodoray, P | 1 |
| Gómez Carrera, L | 1 |
| Álvarez-Sala Walther, R | 1 |
| Bowling, MR | 1 |
| Cauthen, CG | 1 |
| Perry, CD | 1 |
| Patel, NP | 1 |
| Bergman, S | 1 |
| Link, KM | 1 |
| Sane, AC | 1 |
| Conforti, JF | 1 |
| Roig, V | 1 |
| Herrero, A | 1 |
| Arroyo-Cózar, M | 1 |
| Vielba, D | 1 |
| Juarros, S | 1 |
| Macías, E | 1 |
| Spagnolo, P | 1 |
| Del Giovane, C | 1 |
| Luppi, F | 1 |
| Cerri, S | 1 |
| Balduzzi, S | 1 |
| Walters, EH | 2 |
| D'Amico, R | 1 |
| Richeldi, L | 2 |
| Bussone, G | 1 |
| Mouthon, L | 1 |
| Child, N | 1 |
| O'Carroll, M | 1 |
| Berkahn, L | 1 |
| Raghu, G | 2 |
| Anstrom, KJ | 1 |
| King, TE | 2 |
| Lasky, JA | 1 |
| Martinez, FJ | 1 |
| Behr, J | 2 |
| Izumi, S | 1 |
| Iikura, M | 1 |
| Hirano, S | 1 |
| Uruga, H | 1 |
| Hanada, S | 1 |
| Kishi, K | 1 |
| Davies, HR | 1 |
| Dai, LJ | 1 |
| Hou, J | 1 |
| Cai, HR | 1 |
| Sarahrudi, K | 1 |
| Estenne, M | 1 |
| Corris, P | 1 |
| Niedermayer, J | 1 |
| Knoop, C | 1 |
| Glanville, A | 1 |
| Chaparro, C | 1 |
| Verleden, G | 1 |
| Gerbase, MW | 1 |
| Venuta, F | 1 |
| Böttcher, H | 1 |
| Aubert, JD | 1 |
| Levvey, B | 1 |
| Reichenspurner, H | 1 |
| Auterith, A | 1 |
| Klepetko, W | 1 |
| Sharma, S | 1 |
| Field, SK | 1 |
| Pereira, CA | 1 |
| Malheiros, T | 1 |
| Coletta, EM | 1 |
| Ferreira, RG | 1 |
| Rubin, AS | 1 |
| Otta, JS | 1 |
| Rocha, NS | 1 |
| Demedts, M | 1 |
| Buhl, R | 1 |
| Costabel, U | 2 |
| Dekhuijzen, R | 1 |
| Jansen, HM | 1 |
| MacNee, W | 1 |
| Thomeer, M | 1 |
| Wallaert, B | 2 |
| Laurent, F | 1 |
| Nicholson, AG | 1 |
| Verbeken, EK | 1 |
| Verschakelen, J | 1 |
| Flower, CD | 1 |
| Capron, F | 1 |
| Petruzzelli, S | 1 |
| De Vuyst, P | 1 |
| van den Bosch, JM | 1 |
| Rodriguez-Becerra, E | 1 |
| Corvasce, G | 1 |
| Lankhorst, I | 1 |
| Sardina, M | 1 |
| Montanari, M | 1 |
| Hunninghake, GW | 1 |
| Nathan, SD | 1 |
| Wells, AU | 2 |
| Günther, A | 1 |
| Markart, P | 1 |
| Eickelberg, O | 1 |
| Seeger, W | 1 |
| Walter, N | 1 |
| Collard, HR | 1 |
| Dury, S | 1 |
| Bennett, L | 1 |
| Crouse, R | 1 |
| Feldstein, D | 1 |
| Hoyles, RK | 1 |
| Ellis, RW | 1 |
| Wellsbury, J | 1 |
| Lees, B | 1 |
| Newlands, P | 1 |
| Goh, NS | 1 |
| Roberts, C | 1 |
| Desai, S | 1 |
| Herrick, AL | 1 |
| McHugh, NJ | 1 |
| Foley, NM | 1 |
| Pearson, SB | 1 |
| Emery, P | 1 |
| Veale, DJ | 1 |
| Denton, CP | 1 |
| Black, CM | 1 |
| du Bois, RM | 1 |
| Churg, A | 1 |
| Müller, NL | 1 |
| Silva, CI | 1 |
| Wright, JL | 1 |
| Perri, D | 1 |
| Cole, DE | 1 |
| Friedman, O | 1 |
| Piliotis, E | 1 |
| Mintz, S | 1 |
| Adhikari, NK | 1 |
| Gomes, MF | 1 |
| de Sousa, GV | 1 |
| Nogueira, JB | 1 |
| Witte, L | 1 |
| Rupp, J | 1 |
| Heyer, P | 1 |
| Dalhoff, K | 1 |
| Schaaf, B | 1 |
| Stiefelhagen, P | 1 |
| Il'kovich, MM | 1 |
| Carmichael, DJ | 1 |
| Hamilton, DV | 1 |
| Evans, DB | 1 |
| Stovin, PG | 1 |
| Calne, RY | 1 |
| Bedrossian, CW | 1 |
| Sussman, J | 1 |
| Conklin, RH | 1 |
| Kahan, B | 1 |
| Lanser, K | 1 |
| von Wichert, P | 1 |
| Lawson, DH | 1 |
| Lovatt, GE | 1 |
| Gurton, CS | 1 |
| Hennings, RC | 1 |
| Fergusson, RJ | 1 |
| Davidson, NM | 1 |
| Nuki, G | 1 |
| Crompton, GK | 1 |
| Strumeliev, S | 1 |
| Rubin, R | 1 |
| Rudd, RM | 1 |
| Haslam, PL | 1 |
| Turner-Warwick, M | 2 |
| Matthys, H | 2 |
| Dundalek, E | 1 |
| Duroux, P | 1 |
| Simonneau, G | 1 |
| Cerrina, J | 1 |
| Salmona, JP | 1 |
| Chrétien, J | 1 |
| Maher, J | 1 |
| Daly, PA | 1 |
| Marwaha, RK | 1 |
| Garewal, G | 1 |
| Kumar, V | 1 |
| Sarkar, B | 1 |
| Malik, N | 1 |
| Nicod, LP | 2 |
| McCune, WJ | 1 |
| Vallance, DK | 1 |
| Lynch, JP | 1 |
| Yamakido, M | 1 |
| Peters, SG | 1 |
| McDougall, JC | 1 |
| Douglas, WW | 1 |
| Coles, DT | 1 |
| DeRemee, RA | 1 |
| Pérez de Llano, LA | 1 |
| Lancho, A | 1 |
| Soilán del Cerro, JL | 1 |
| López-Róses, L | 1 |
| Sauty, A | 1 |
| Rochat, T | 1 |
| Schoch, OD | 1 |
| Hamacher, J | 1 |
| Kurt, AM | 1 |
| Dayer, JM | 1 |
| Salez, F | 1 |
| Lamblin, C | 1 |
| Roboubi, R | 1 |
| Egan, J | 1 |
| Bourke, SC | 1 |
| Clague, H | 1 |
| Lode, H | 2 |
| Erbes, R | 2 |
| Raffenberg, M | 1 |
| Komócsi, A | 1 |
| Kumánovics, G | 1 |
| Zibotics, H | 1 |
| Czirják, L | 1 |
| Baughman, RP | 1 |
| Alabi, FO | 1 |
| Storb, R | 1 |
| Matthay, RA | 1 |
| Schwarz, MI | 1 |
| Petty, TL | 1 |
| Stanford, RE | 1 |
| Gupta, RC | 1 |
| Sahn, SA | 1 |
| Steigerwald, JC | 1 |
| Meier-Sydow, J | 3 |
| Rust, M | 1 |
| Kronenberger, H | 1 |
| Thiel, C | 2 |
| Amthor, M | 1 |
| Riemann, H | 1 |
| Cegla, UH | 6 |
| Weisenburger, DD | 1 |
| Winterbauer, RH | 3 |
| Hammar, SP | 2 |
| Hallman, KO | 1 |
| Hays, JE | 1 |
| Pardee, NE | 2 |
| Morgan, EH | 1 |
| Allen, JD | 1 |
| Moores, KD | 1 |
| Bush, W | 1 |
| Walker, JH | 1 |
| Cohen, JM | 1 |
| Miller, A | 1 |
| Spiera, H | 1 |
| Barnes, SE | 1 |
| Godfrey, S | 1 |
| Millward-Sadler, GH | 1 |
| Roberton, NR | 1 |
| Kroidl, RF | 1 |
| Czarnecki, G | 1 |
| Schreiber, F | 1 |
| Weese, WC | 1 |
| Levine, BW | 1 |
| Kazemi, H | 1 |
| Shishido, M | 1 |
| Ichiki, H | 1 |
| Yano, M | 1 |
| Toda, K | 1 |
| Ohtsuki, Y | 1 |
| Brown, AL | 1 |
| Corris, PA | 1 |
| Ashcroft, T | 1 |
| Wilkinson, R | 1 |
| Murnaghan, DJ | 1 |
| Doré, P | 1 |
| Meurice, JC | 1 |
| Recart, D | 1 |
| Patte, F | 1 |
| Riedler, J | 1 |
| Golser, A | 1 |
| Huttegger, I | 1 |
| Sasaki, F | 1 |
| Ishizaki, T | 1 |
| Miyabo, S | 1 |
| Shigematsu, N | 1 |
| Nagata, N | 1 |
| Muranishi, H | 1 |
| Hayashi, S | 1 |
| Inuzuka, S | 1 |
| Depaso, WJ | 1 |
| Cain, K | 1 |
| Wetzel, CE | 1 |
| Dreis, DF | 1 |
| Hutchinson, J | 1 |
| Witt, C | 1 |
| Neuhaus, K | 1 |
| Winsel, K | 1 |
| Brenke, A | 1 |
| Hiepe, F | 1 |
| Volk, HD | 1 |
| Khomenko, AG | 1 |
| Shmelev, EI | 1 |
| Stepanian, IE | 1 |
| Dmitrieva, LI | 1 |
| Kalinin, NN | 1 |
| Liebetrau, G | 1 |
| Fukazawa, M | 1 |
| Kawano, M | 1 |
| Hisano, S | 1 |
| Ueda, K | 1 |
| Matsuba, K | 1 |
| Harazawa, M | 1 |
| Ishida, K | 1 |
| Fukuchi, Y | 1 |
| Usuba, Y | 1 |
| Aiba, S | 1 |
| Hashimoto, K | 1 |
| Tanita, Y | 1 |
| Sakai, K | 1 |
| Clements, PJ | 1 |
| Davis, J | 1 |
| Smith, CM | 1 |
| Moser, KM | 1 |
| Gruhn, WB | 1 |
| Diaz-Buxo, JA | 1 |
| Roschmann, RA | 1 |
| Rothenberg, RJ | 1 |
| Izdebska-Makosa, Z | 1 |
| Zielinski, J | 2 |
| Demeter, SL | 1 |
| Skwarski, K | 1 |
| Strausz, J | 1 |
| Schweiger, O | 1 |
| Sperryn, PN | 1 |
| Mace, BE | 1 |
| Hugh-Jones, P | 1 |
| Macarthur, AM | 1 |
| Cullum, PA | 1 |
| Mason, SA | 1 |
| Crosbie, WA | 1 |
| Hutchison, DC | 1 |
| Winterton, MC | 1 |
| Smith, AP | 1 |
| Mason, B | 1 |
| Smith, LA | 1 |
| Joseph, RR | 1 |
| Tourtellotte, CD | 1 |
| Barry, WE | 1 |
| Smalley, RV | 1 |
| Durant, JR | 1 |
| Zubler, RH | 1 |
| Kapanci, Y | 1 |
| Miescher, PA | 1 |
| Dierkesmann, R | 1 |
| Kroidl, R | 1 |
| Schlehe, H | 1 |
| Konietzko, N | 1 |
| Altenstetter, F | 1 |
| Haas, W | 1 |
| Münzenmaier, R | 1 |
| Loewe, KR | 1 |
| Byrd, RB | 1 |
| Gracey, DR | 1 |
| Benson, MK | 1 |
| Hughes, DT | 1 |
| Steiger, RP | 1 |
| Brown, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial[NCT05674994] | Phase 3 | 110 participants (Anticipated) | Interventional | 2023-10-26 | Recruiting | ||
| Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF[NCT00650091] | Phase 3 | 264 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa[NCT05537220] | Phase 3 | 438 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial[NCT02460588] | Phase 3 | 120 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients[NCT01429844] | Phase 3 | 274 participants (Actual) | Interventional | 2001-01-31 | Completed | ||
| Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)[NCT00639496] | Phase 3 | 184 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)[NCT01199887] | Phase 1 | 30 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease[NCT01862926] | Phase 2/Phase 3 | 104 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| A Randomized Controlled Trial to Compare the Efficacy of Oral Mycophenolate Mofetil With Placebo in Patients With Systemic Sclerosis Related Early Interstitial Lung Disease[NCT02896205] | Phase 3 | 41 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Chronotherapy in Inflammatory Bowel Disease[NCT04304950] | Phase 4 | 28 participants (Actual) | Interventional | 2016-04-25 | Completed | ||
| Sun Yat-sen Memorial Hospital[NCT02985346] | Early Phase 1 | 100 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions:~1. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax." (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | events (Number) |
|---|---|
| N-Acetylcysteine | 3 |
| Placebo | 3 |
"The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression.~The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline." (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | percentage of participants (Number) |
|---|---|
| N-Acetylcysteine | 27.1 |
| Placebo | 26.5 |
Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline. (NCT00650091)
Timeframe: Measured at Week 60
| Intervention | participants (Number) |
|---|---|
| N-Acetylcysteine | 29 |
| Placebo | 35 |
Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters) (NCT00650091)
Timeframe: Measured as the estimated change from baseline to Week 60
| Intervention | liters (Mean) |
|---|---|
| N-Acetylcysteine | -0.18 |
| Placebo | -0.19 |
(NCT00650091)
Timeframe: Measured at Week 60
| Intervention | events (Number) |
|---|---|
| N-Acetylcysteine | 6 |
| Placebo | 6 |
Change from Baseline in Forced Vital Capacity at 15, 30, 45, and 60 weeks (units in liters) (NCT00650091)
Timeframe: Baseline, 15, 30, 45, 60 week
| Intervention | liters (Mean) | |||
|---|---|---|---|---|
| 15 week | 30 week | 45 week | 60 week | |
| N-Acetylcysteine | -0.07 | -0.07 | -0.15 | -0.16 |
| Placebo | -0.04 | -0.08 | -0.15 | -0.15 |
This is to examine if the intervention results in a lower level of 6-Methylmercaptopurine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10 ^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 2395.27 |
| Morning Group Medication Administration | 825.15 |
Harvey Bradshaw Activity Index has 5 questions. The final score is totaled and will fall into the following categories, which are used to define the severity of the disease: >16 severe diseases, 8-16 moderate disease, 5-7 mild disease, <5 remission. Scores range from 0 ( lowest possible score) to 17. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 2.15 |
| Morning Group Medication Administration | 3.09 |
This questionnaire is used to collect primary sleep times, such as bed- and rise-times, including the time a person is fully awake, sleep latency and inertia, in addition to other time points. The MCTQ uses the midpoint of sleep between sleep onset and offset to assess chronotype. Chronotype is your body's natural time to be awake or asleep at certain times. Total scores can range from 16 to 86, with the lowest values representing extreme-late chronotype. For this study corrected midpoint of sleep (MSFc) was calculated. This information is combined to determine the mean time of day at which respondents were more likely to feel most alert. The numbers provided in the outcome measure data table represent time (hour and minute). The hour has been converted to military time and the minutes were converted to decimals. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | hours (Mean) |
|---|---|
| Evening Group Medication Administration | 3.70 |
| Morning Group Medication Administraion | 2.57 |
Quality of Life Measure Score:1-7 (The higher the number the greater the quality of life) (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | units on a scale (Mean) |
|---|---|
| Evening Group Medication Administration | 5.83 |
| Morning Group Medication Administration | 5.91 |
This is to examine if the intervention results in a greater level of thioguanine in the participants. If so, the participants are expected to have less symptom severity. Comparing baseline taken at visit one to visit two levels 10 weeks after intervention start. (NCT04304950)
Timeframe: 10 weeks post baseline visit.
| Intervention | pmol/8 x 10^8 RBC (Mean) |
|---|---|
| Evening Group Medication Administration | 175.04 |
| Morning Group Medication Administration | 225.65 |
24 reviews available for azathioprine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Non-steroid agents for idiopathic pulmonary fibrosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colchicine; Cyclophosphamide; Humans; Immunos | 2010 |
Interstitial lung disease in systemic sclerosis.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Azathioprine; Contraindications; Cyclophosph | 2011 |
[Treatment of pulmonary fibrosis].
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Apo | 2002 |
Immunomodulatory agents for idiopathic pulmonary fibrosis.
Topics: Azathioprine; Colchicine; Cyclophosphamide; Humans; Immunosuppressive Agents; Interferon-gamma; Pred | 2003 |
Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.
Topics: Acetylcysteine; Azathioprine; Benzamides; Bosentan; Clinical Trials as Topic; Cyclophosphamide; Drug | 2006 |
[Pulmonary fibrosis--a therapeutic dilemma?].
Topics: Acetylcysteine; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Benz | 2006 |
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anticoagulants; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Humans; Im | 2006 |
[Idiopathic interstitial pneumonia: treatment].
Topics: Acetylcysteine; Acute Disease; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Azathioprine; Benz | 2006 |
[Treatment of patients with idiopathic fibrosing alveolitis (personal experience and information from the literature)].
Topics: Adrenal Cortex Hormones; Azathioprine; Drug Therapy, Combination; Humans; Penicillamine; Pulmonary F | 1983 |
Adverse effects of azathioprine.
Topics: Alopecia; Azathioprine; Bone Marrow Diseases; Carcinogens; Drug Hypersensitivity; Drug Interactions; | 1984 |
[Diffuse fibrosing alveolitis (author's transl)].
Topics: Azathioprine; Humans; Lung; Penicillamine; Prednisone; Pulmonary Fibrosis | 1981 |
[Fibrosing alveolitis (interstitial pneumonia)].
Topics: Adrenal Cortex Hormones; Azathioprine; Connective Tissue; Drug Therapy, Combination; Humans; Lung; P | 1982 |
Immunosuppressive drug therapy.
Topics: Adrenal Cortex Hormones; Azathioprine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Cyc | 1994 |
[Recent progress on diagnosis and therapy of pulmonary fibrosis].
Topics: Acute Disease; Azathioprine; Chronic Disease; Humans; Prednisolone; Prognosis; Pulmonary Fibrosis; R | 1993 |
Medical treatment for idiopathic pulmonary fibrosis.
Topics: Adrenal Cortex Hormones; Antimetabolites; Azathioprine; Cyclophosphamide; Humans; Pulmonary Fibrosis | 1997 |
Pharmacologic therapy of idiopathic pulmonary fibrosis.
Topics: Adrenal Cortex Hormones; Azathioprine; Colchicine; Cyclophosphamide; Cyclosporine; Humans; Pulmonary | 1998 |
Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combination; Environmental Pollutants; F | 2000 |
Nonsteroidal therapy for idiopathic pulmonary fibrosis.
Topics: Azathioprine; Colchicine; Cyclophosphamide; Cytokines; Female; Fibroblasts; Humans; Immunosuppressiv | 2001 |
Bone marrow transplantation for the treatment of aplastic anemia and acute leukemia.
Topics: Acute Disease; Anemia, Aplastic; Azathioprine; Blood Platelets; Blood Transfusion; Bone Marrow Trans | 1978 |
[Therapeutic possibilities in alveolitis and pulmonary fibrosis].
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Azathioprine; Humans; Penicillamine; Pulmon | 1990 |
[A fatal case of pemphigus vulgaris with interstitial pneumonia occurring during gold therapy].
Topics: Azathioprine; Drug Therapy, Combination; Female; Gold Sodium Thiomalate; Humans; Middle Aged; Pemphi | 1989 |
Cytotoxic drugs: their clinical application to the rheumatic diseases.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Behcet Syndrome; Bone Marrow; Cell Division; Chemica | 1986 |
Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.
Topics: Adult; Azathioprine; Cyclosporins; Dermatomyositis; Drug Resistance; Female; Humans; Myositis; Predn | 1987 |
Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Fe | 1987 |
7 trials available for azathioprine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Treatment switching in idiopathic pulmonary fibrosis: from triple therapy to enrollment into a clinical investigational drug trial.
Topics: Acetylcysteine; Azathioprine; Double-Blind Method; Drugs, Investigational; Humans; Idiopathic Pulmon | 2013 |
[Comparative study between oral azathioprine and intravenous cyclophosphamide pulses in the treatment of idiopathic pulmonary fibrosis].
Topics: Administration, Oral; Adult; Aged; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive | 2010 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Azathioprine; Disease Progression; Double-Blind Method; Drug Therapy, Combinat | 2012 |
High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Double-Blind Method; Dru | 2005 |
High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Double-Blind Method; Dru | 2005 |
High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Double-Blind Method; Dru | 2005 |
High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Double-Blind Method; Dru | 2005 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Double-Blind Method; | 2006 |
[Long-term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprin or d-penicillamine (author's transl)].
Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Humans; Penicillamine; | 1979 |
Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.
Topics: Azathioprine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pre | 1991 |
81 other studies available for azathioprine and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension--clinical management.
Topics: Acetylcysteine; Azathioprine; Disease Management; Humans; Hypertension, Pulmonary; Lung; Male; Middl | 2013 |
Mixed connective tissue disease associated with autoimmune hepatitis and pulmonary fibrosis.
Topics: Adult; Azathioprine; Biopsy; Bronchoscopy; Disease Progression; Female; Hepatitis, Autoimmune; Human | 2014 |
[Pulmonary fibrosis].
Topics: Acetylcysteine; Azathioprine; Clinical Trials as Topic; Forecasting; Glucocorticoids; Humans; Indole | 2016 |
Pulmonary extramedullary hematopoiesis.
Topics: Anemia, Hemolytic; Antirheumatic Agents; Arthritis; Azathioprine; Biopsy, Fine-Needle; Diagnosis, Di | 2008 |
Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Combined Modality Therapy; | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Azathioprine; Female; Humans; Male; Prednisone; Pulmonary Fibrosis | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Azathioprine; Female; Humans; Male; Prednisone; Pulmonary Fibrosis | 2012 |
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Topics: Acetylcysteine; Azathioprine; Female; Humans; Male; Prednisone; Pulmonary Fibrosis | 2012 |
[Experimental study on treatment of pulmonary fibrosis by Chinese drugs and integrative Chinese and Western medicine].
Topics: Animals; Astragalus propinquus; Azathioprine; Bleomycin; Drugs, Chinese Herbal; Hydrocortisone; Phyt | 2004 |
International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection.
Topics: Acute Disease; Adult; Australia; Azathioprine; Bronchiolitis Obliterans; Canada; Chronic Disease; Cy | 2004 |
Steroids and/or cytotoxic agents should be used early in the management of patients with IPF--the pro argument.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic A | 2004 |
Steroids and/or cytotoxic agents should be used early in the management of patients with IPF - the con argument.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic A | 2004 |
Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids.
Topics: Aged; Antimetabolites, Antineoplastic; Azathioprine; Brazil; Cohort Studies; Cyclophosphamide; Femal | 2006 |
Antioxidant therapy for idiopathic pulmonary fibrosis.
Topics: Acetylcysteine; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Drug Therapy, Combination; Glu | 2005 |
Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled.
Topics: Acetylcysteine; Antioxidants; Azathioprine; Controlled Clinical Trials as Topic; Drug Therapy, Combi | 2006 |
[Treatment of idiopathic pulmonary fibrosis].
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Cyclopho | 2006 |
Clinical use of evidence-based medicine--clinical questions: Acetylcysteine, a new treatment for an old foe?
Topics: Acetylcysteine; Aged; Anti-Inflammatory Agents; Antioxidants; Azathioprine; Drug Therapy, Combinatio | 2006 |
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Cyclophosphamide; Disease Progres | 2007 |
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Cyclophosphamide; Disease Progres | 2007 |
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Cyclophosphamide; Disease Progres | 2007 |
Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
Topics: Adult; Aged; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Cyclophosphamide; Disease Progres | 2007 |
Azathioprine and diffuse alveolar haemorrhage: the pharmacogenetics of thiopurine methyltransferase.
Topics: Azathioprine; Female; Hemorrhage; Humans; Immunosuppressive Agents; Lung Diseases; Male; Methyltrans | 2007 |
Idiopathic pulmonary fibrosis in a young patient.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azathioprine; Azithromy | 2008 |
[Fibrosing alveolitis with hepatitis C-related cryoglobulinemia].
Topics: Azathioprine; Bronchoalveolar Lavage; Cryoglobulinemia; Cryoglobulins; Glucocorticoids; Hepatitis C; | 2008 |
[Increasing dyspnea: myocardial infarction anamnesis led to wrong track].
Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Diagnosis, Differential; Dyspnea; Female; Humans; Immun | 2005 |
Interstitial pneumonitis secondary to azathioprine in a renal transplant patient.
Topics: Adult; Azathioprine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation; Prednisolone | 1983 |
Azathioprine-associated interstitial pneumonitis.
Topics: Adult; Aged; Azathioprine; Basement Membrane; Epithelium; Female; Graft Rejection; Humans; Kidney Tr | 1984 |
[What is safe in the therapy of alveolitis and lung fibrosis?].
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Azathioprine; Combined Modality Therapy; Cy | 1984 |
Dermatomyositis and rapidly progressive fibrosing alveolitis.
Topics: Aged; Azathioprine; Dermatomyositis; Female; Humans; Male; Middle Aged; Prednisolone; Pulmonary Fibr | 1983 |
Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis.
Topics: Adult; Aged; Azathioprine; Bronchi; Cyclophosphamide; Female; Humans; Male; Middle Aged; Penicillami | 1981 |
Different therapies and factors influencing response to therapy in idiopathic diffuse fibrosing alveolitis.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillami | 1981 |
[Drug therapy of lung fibrosis].
Topics: Azathioprine; Cortisone; Humans; Penicillamine; Pulmonary Fibrosis; Spironolactone | 1981 |
[Treatment of diffuse interstitial fibrosis].
Topics: Adrenal Cortex Hormones; Azathioprine; Humans; Pulmonary Fibrosis | 1980 |
[Idiopathic fibrogenous interstitial pneumopathy].
Topics: Adrenal Cortex Hormones; Azathioprine; Coronary Disease; Humans; Lung; Lung Neoplasms; Pulmonary Fib | 1980 |
Severe bleomycin lung toxicity: reversal with high dose corticosteroids.
Topics: Adult; Azathioprine; Bleomycin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lun | 1993 |
Microcytic hypochromic anemia in idiopathic pulmonary hemosiderosis: a diagnostic pitfall.
Topics: Anemia, Hypochromic; Azathioprine; Child; Child, Preschool; Diagnosis, Differential; Fatal Outcome; | 1994 |
[Treatment of idiopathic pulmonary fibrosis].
Topics: Azathioprine; Colchicine; Cyclophosphamide; Cyclosporine; Diagnosis, Differential; Humans; Lung Dise | 1995 |
Colchicine in the treatment of pulmonary fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Biopsy; Bronchoscopy; Colchicine; Cyclophosphamide; Fe | 1993 |
Cryptogenic fibrosing alveolitis predating ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 1996 |
Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies.
Topics: Aged; Antibodies, Antinuclear; Autoantibodies; Azathioprine; Biopsy, Needle; Bronchoalveolar Lavage | 1997 |
[Idiopathic pulmonary fibrosis. II. Treatment].
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combinat | 2001 |
[Idiopathic pulmonary fibrosis. III. Case report].
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combinati | 2001 |
Alveolitis may persist during treatment that sufficiently controls muscle inflammation in myositis.
Topics: Adult; Aged; Azathioprine; Bronchoalveolar Lavage Fluid; Dermatomyositis; Drug Therapy, Combination; | 2001 |
Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Azathioprine; Cardiomegaly; Female; Humans; Lung Volume Meas | 1975 |
[Idiopathic fibrosing alveolitis (IFA)--clinical characteristics, cardiopulmonary functions, and therapeutic methods].
Topics: Adult; Azathioprine; Child; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prednisolo | 1978 |
Interstitial pneumonitis associated with azathioprine therapy.
Topics: Adult; Azathioprine; Female; Glomerulonephritis; Humans; Lung; Pulmonary Fibrosis | 1978 |
Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Lung; Male; Middle Aged; Pneum | 1978 |
[Treatment of idiopathic fibrosing alveolitis. Therapeutic experiences with azathioprine-prednisolone and D-penicillamine-prednisolone combination therapy].
Topics: Adult; Aged; Azathioprine; Capillary Permeability; Drug Therapy, Combination; Female; Humans; Male; | 1977 |
Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy.
Topics: Arthritis, Rheumatoid; Azathioprine; Female; Humans; Middle Aged; Pneumonia; Pulmonary Fibrosis; Res | 1977 |
[Idiopathic fibrosing alveolitis].
Topics: Azathioprine; Drug Therapy, Combination; Female; Humans; Life Expectancy; Lung Compliance; Male; Par | 1977 |
[Some pharmacological facts for the therapy of idiopathic fibrosing alveolitis (author's transl)].
Topics: Azathioprine; Drug Therapy, Combination; Humans; Penicillamine; Prednisolone; Pulmonary Fibrosis | 1976 |
Desquamative fibrosing alveolitis unresponsive to steroid or cytotoxic therapy.
Topics: Azathioprine; Eosinophils; Humans; Immunosuppression Therapy; Infant; Lung; Male; Oxygen Inhalation | 1975 |
Therapy of the idiopathic fibrosis of the lung.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminobenzoates; Azathioprine; Drug Therapy, Combination; Femal | 1975 |
[Proceedings: Round table discussion: Differential diagnosis and therapy of interstitial lung diseases].
Topics: Azathioprine; Biopsy; Diagnosis, Differential; Humans; Lung; Lung Compliance; Penicillamine; Prednis | 1975 |
Interstitial lung disease resistant to corticosteroid therapy. Report of three cases treated with azathioprine or cyclophosphamide.
Topics: Adult; Azathioprine; Cyclophosphamide; Humans; Immunosuppression Therapy; Male; Middle Aged; Prednis | 1975 |
[A case of idiopathic pulmonary fibrosis with histology of usual interstitial pneumonia that responded to pulse therapy followed by combined immunosuppression with prednisolone and azathioprine].
Topics: Aged; Azathioprine; Female; Humans; Immunosuppressive Agents; Methylprednisolone; Prednisolone; Pulm | 1992 |
Azathioprine-related interstitial pneumonitis in a renal transplant recipient.
Topics: Azathioprine; Humans; Kidney Transplantation; Male; Middle Aged; Pulmonary Fibrosis | 1992 |
Azathioprine-related interstitial pneumonitis in a renal transplant recipient.
Topics: Azathioprine; Humans; Kidney Transplantation; Pulmonary Fibrosis | 1992 |
[Reaction of hypersensitivity to azathioprine].
Topics: Azathioprine; Drug Hypersensitivity; Humans; Male; Middle Aged; Pulmonary Fibrosis | 1992 |
Fibrosing alveolitis in an infant.
Topics: Azathioprine; Drug Therapy, Combination; Female; Humans; Hypoxia; Infant; Lung; Oxygen; Prednisone; | 1992 |
[Plasmapheresis in pulmonary fibrosis].
Topics: Azathioprine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Methylprednis | 1992 |
[Drug-induced interstitial lung diseases].
Topics: Antineoplastic Agents; Antirheumatic Agents; Azathioprine; Bleomycin; Humans; Methotrexate; Organogo | 1990 |
[Bronchoalveolar lavage in patients with systemic scleroderma and systemic lupus erythematosus: characterization of cell activity by cytofluorometry, chemiluminescence and differential cell count].
Topics: Adult; Azathioprine; B-Lymphocyte Subsets; Bronchoalveolar Lavage Fluid; Female; Flow Cytometry; Hum | 1991 |
The treatment of idiopathic pulmonary fibrosis.
Topics: Adrenal Cortex Hormones; Azathioprine; Biopsy; Cyclophosphamide; Humans; Lung; Pulmonary Fibrosis | 1991 |
[Use of plasmacytapheresis in combined modality therapy of patients with fibrosing alveolitis].
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Blood Component Removal; Combined Modality Thera | 1991 |
Efficacy of cyclosporin A for idiopathic pulmonary fibrosis.
Topics: Administration, Oral; Azathioprine; Child; Cyclosporins; Drug Therapy, Combination; Female; Humans; | 1990 |
[Idiopathic interstitial pneumonia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Female; Humans; I | 1990 |
Management for interstitial lung disease. State of the art.
Topics: Azathioprine; Biopsy; Bronchoalveolar Lavage Fluid; Cyclophosphamide; Humans; Middle Aged; Prednison | 1989 |
Primary biliary cirrhosis in a patient with interstitial lung fibrosis.
Topics: Azathioprine; Humans; Liver Cirrhosis; Male; Middle Aged; Prednisolone; Pulmonary Fibrosis | 1987 |
Interstitial vasculitis--interstitial lung disease: case studies.
Topics: Adult; Aged; Azathioprine; Bronchodilator Agents; Female; Humans; Male; Middle Aged; Oxygen Consumpt | 1986 |
Pulmonary hypertension in a patient with diffuse fibrosing alveolitis due to rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Humans; Hypertension, Pulmonary; Male; Pulmonary Fibrosi | 1986 |
[Interstitial lung diseases].
Topics: Adrenal Cortex Hormones; Azathioprine; Cyclophosphamide; Follow-Up Studies; Humans; Pulmonary Fibros | 1985 |
Systemic lupus erythematosus with fibrosing alveolitis.
Topics: Azathioprine; Humans; Lupus Erythematosus, Systemic; Male; Neutrophils; Prednisolone; Pulmonary Fibr | 1971 |
Lung transplantation in a patient with fibrosing alveolitis.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Dactinomycin; Graft Rejection; Humans; Immunosuppression | 1971 |
Prolonged immunological disorder terminating in hematological malignancy: A human analogue of animal disease?
Topics: Aged; Animal Diseases; Animals; Autoimmune Diseases; Azathioprine; Blood Protein Disorders; Blood Pr | 1970 |
Steroid drugs in chest disease.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Asthma; Azathioprine; Humans; Hydrocortisone; | 1972 |
[A case of interstitial lymphoid pneumonia treated with immunosuppressors].
Topics: Adult; Azathioprine; Carbon Dioxide; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosupp | 1974 |
[Therapy of diffuse pulmonary fibrosis (including prevention of development and progression)].
Topics: Adrenal Cortex Hormones; Azathioprine; Biopsy; Bronchitis; Collagen Diseases; Humans; Immunosuppress | 1974 |
[Therapy of idiopathic diffuse pulmonary fibrosis].
Topics: Adult; Aged; Azathioprine; Corticosterone; Female; Humans; Male; Middle Aged; Partial Pressure; Plet | 1973 |
[Nitrofurantoin-induced chronic pulmonary fibrosis (author's transl)].
Topics: Adrenal Cortex Hormones; Aged; Azathioprine; Chronic Disease; Fever; Humans; Male; Nitrofurantoin; P | 1973 |
Immunosuppressive treatment of idiopathic pulmonary hemosiderosis.
Topics: Adult; Azathioprine; Hemoptysis; Hemosiderosis; Humans; Immunosuppression Therapy; Lung Diseases; Ma | 1973 |
Serial pulmonary function tests in fibrosing alveolitis.
Topics: Adult; Azathioprine; Biopsy; Dyspnea; Female; Humans; Lung; Male; Middle Aged; Prednisone; Pulmonary | 1972 |
[Etiology and therapy of idiopathic lung hemosideroses].
Topics: Adult; Azathioprine; Cortisone; Female; Hematuria; Hemosiderosis; Humans; Iron; Lung Diseases; Pulmo | 1966 |
The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs.
Topics: Adult; Agglutination Tests; Antibodies, Antinuclear; Azathioprine; Chlorambucil; Complement Fixation | 1971 |